Efficacy News and Research

RSS

MD65 IgG-YTE shows powerful post-exposure neutralization of SARS-CoV-2

A recent study published in the preprint server bioRxiv in October 2020 describes a reliable animal model to demonstrate the powerful capacity of human neutralizing mAbs directed against SARS-CoV-2 to prevent viral binding the host cell receptor and thus block infection. This indicates the lifesaving value of mAbs in severe COVID-19.

29 Oct 2020

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

University Hospitals and Case Western Reserve University announced today that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca.

29 Oct 2020

Researchers identify a novel SARS-CoV-2 variant that spread widely across Europe in summer 2020

Researchers from Basel and Spain have identified a novel SARS-CoV-2 variant that has spread widely across Europe in recent months, according to an un-peer-reviewed preprint released this week.

29 Oct 2020

New therapeutic approach brings hope for treating psoriasis

Disruptive innovations in psoriasis are leading the way at EADV's 29th Congress, EADV Virtual. New data published today shows the first clinical evidence of modulating systemic inflammation by oral delivery of a non-living single strain commensal microbe.

29 Oct 2020

REACT study shows 26% decline in SARS CoV-2 seroprevalence over 2-3 months

Their study titled, "Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults," was released online as a pre-print on the medRxiv* server. This large study was funded by the Department of Health and Social Care in England.

28 Oct 2020

Genome-wide CRISPR screens reveal resistance and sensitization mechanisms of drugs used in COVID-19

By leveraging nucleotide triphosphate analog-induced cell death, Chinese researchers unveiled genes that affect the import, export, and metabolism of pervasively used antiviral drugs in the treatment of coronavirus disease (COVID-19). This exciting study is currently available on the bioRxiv* preprint server.

28 Oct 2020

Novel cardiac patch improves recovery from heart attack in rats and pigs

According to the American Heart Association, heart disease is the leading cause of death worldwide in recent years.

28 Oct 2020

New portable arm rehabilitation device launched to help patients perform robot-aided therapy at home

A new portable arm rehabilitation robot will help patients to carry out robot-aided therapy at home, allowing them to perform intensive exercises without visiting hospitals or clinics, which can possibly reduce the risk of exposure to infectious diseases such as COVID-19.

28 Oct 2020

Scientists warn Americans are expecting too much from a vaccine

The White House and many Americans have pinned their hopes for defeating the COVID-19 pandemic on a vaccine being developed at "warp speed." But some scientific experts warn they're all expecting too much, too soon.

28 Oct 2020

Inflammasome may play a key role in triggering immune response to cancer

The inflammasome — a protein signaling network that is activated to rid the body of virus or bacteria-infected cells — may play an important role in triggering an immune response to cancer and causing an existing class of drugs to work better against cancers.

27 Oct 2020

Rapid CD169 assay for COVID-19 screening

Researchers in France have conducted a study demonstrating the sensitivity of a rapid flow cytometry assay that could be used to screen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

27 Oct 2020

Phase II NRG Oncology trial evaluates two regimens for muscle-invasive bladder cancer

Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

27 Oct 2020

Radiation therapy before CART-BCMA appears to be a safe option for multiple myeloma patients

Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania to be presented Tuesday, October 27, at the virtual American Society for Radiation Oncology Annual Meeting (Abstract #35562).

27 Oct 2020

Frequent testing and isolation/quarantine essential to contain COVID-19

A recent study by researchers at Virginia Tech and Central China Normal University published on the preprint server medRxiv in October 2020 discusses the various interventions required and the level of control required, whether to flatten the curve or reduce the case number.

27 Oct 2020

Researchers identify a new way to prevent skin reactions in cancer patients

Using the body's immune system to fight cancer has great potential, but can also bring serious side effects, including itchy and painful skin reactions.

27 Oct 2020

Precise screening index pinpoints areas at risk for low-level lead exposure in Georgia

While many people think of lead poisoning as a problem of the past, chronic exposure still occurs in some communities that may be missed in limited screening programs for children's blood lead levels.

27 Oct 2020

New research on small non-coding RNAs and SARS-CoV-2

A recently published mini-review in the Frontiers in Microbiology on the altered expression of small non-coding RNAs during coronavirus-mediated infections.

26 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

Transcriptomics identifies possible COVID-19 therapies

By using a diverse set of transcriptomic SARS-CoV-2 signatures, US researchers put to use their previously developed drug repositioning pipeline to pinpoint potential drug candidates for the treatment of coronavirus disease (COVID-19). The study is currently available on bioRxiv preprint server.

26 Oct 2020

New inhibitor of SARS-CoV-2 RNA translation

As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.

26 Oct 2020